# Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects

> **NCT01723735** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 79 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Ezetimibe
- **DRUG:** Ezetimibe Placebo
- **DRUG:** Fenofibrate

## Key facts

- **NCT ID:** NCT01723735
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2016-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01723735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01723735, "Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01723735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*